The expression of breast cancer markers, such as estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2/neu), progesterone receptor (PR), and urokinase plasminogen activator (uPA) has been used to evaluate the progression and aggressiveness of the disease [7,8,9]. This evidence concerns the gene ERBB2 and breast carcinoma.